Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00078-0874-63 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Mar 13, 2017 In Use
00078-0860-01 00078-0860 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Mar 13, 2017 In Use
00078-0867-42 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Mar 13, 2017 In Use
00078-0867-14 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Mar 13, 2017 In Use
73555-0500-00 73555-0500 Revumenib Revuforj 25.0 mg/1 Chemotherapy Enzyme Inhibitor KMT2A Oral Nov 15, 2024 In Use
73555-0502-00 73555-0502 Revumenib Revuforj 160.0 mg/1 Chemotherapy Enzyme Inhibitor KMT2A Oral Nov 15, 2024 In Use
73555-0501-00 73555-0501 Revumenib Revuforj 110.0 mg/1 Chemotherapy Enzyme Inhibitor KMT2A Oral Nov 15, 2024 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Mar 22, 2023 In Use
00003-4040-12 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec 5, 2023 In Use
00003-4160-60 00003-4160 Repotrectinib Augtyro 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Nov 1, 2024 In Use
00003-4040-60 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec 5, 2023 In Use
00003-4160-14 00003-4160 Repotrectinib Augtyro 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Nov 1, 2024 In Use
72974-0120-97 72974-0120 Relugolix Orgovyx 120.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Oral Oct 21, 2021 In Use
72974-0120-01 72974-0120 Relugolix Orgovyx 120.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Oral Dec 18, 2020 In Use
72974-0120-95 72974-0120 Relugolix Orgovyx 120.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Oral Jan 27, 2023 In Use
76346-0525-03 76346-0525 Relacorilant Lifyorli 25.0 mg/1, 100.0 mg/1 Chemotherapy Glucocorticoid Receptor (GR) Antagonist Oral Mar 25, 2026 In Use
76346-0550-09 76346-0550 Relacorilant Lifyorli 25.0 mg/1, 100.0 mg/1 Chemotherapy Glucocorticoid Receptor (GR) Antagonist Oral Mar 25, 2026 In Use
76346-0525-09 76346-0525 Relacorilant Lifyorli 25.0 mg/1, 100.0 mg/1 Chemotherapy Glucocorticoid Receptor (GR) Antagonist Oral Mar 25, 2026 In Use
76346-0425-01 76346-0425 Relacorilant Lifyorli 25.0 mg/1, 100.0 mg/1 Chemotherapy Glucocorticoid Receptor (GR) Antagonist Oral Mar 25, 2026 In Use
76346-0450-01 76346-0450 Relacorilant Lifyorli 25.0 mg/1, 100.0 mg/1 Chemotherapy Glucocorticoid Receptor (GR) Antagonist Oral Mar 25, 2026 In Use
76346-0550-03 76346-0550 Relacorilant Lifyorli 25.0 mg/1, 100.0 mg/1 Chemotherapy Glucocorticoid Receptor (GR) Antagonist Oral Mar 25, 2026 In Use
50419-0171-01 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-04 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-03 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-06 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral May 1, 2021 In Use

Found 12393 results — Export these results